Is the FDA About to Restore Access to 14 Peptides? Here’s What Joe Rogan and RFK Jr. Discussed
Recently on The Joe Rogan Experience (Episode #2461), Robert F. Kennedy Jr., now U.S. Department of Health and Human Services (HHS) Secretary, discussed a controversial regulatory issue: the FDA’s treatment of certain therapeutic peptides and plans to reclassify many of them back into a legal prescribing framework. This has sparked widespread attention across biohacking communities, longevity forums, and health-enthusiast networks — not least because of comments on podcasts, social platforms, and trending conversations about peptide availability in 2026. What Was Discussed on The Joe Rogan Experience? On the podcast, RFK Jr. talked about how the Food and Drug Administration (FDA) previously placed about 19 popular peptides into “Category 2”, meaning they were no longer eligible for pharmacy compounding under sections 503A/503B of the Federal Food, Drug, and Cosmetic Act — essentially restricting how doctors and compounding pharmacies could legally make and dispense them. RFK Jr. argued that this shift was based on regulatory overreach — because the FDA *moved them based on perceived efficacy rather than an actual safety signal. He said that about 14 of those peptides would be moved out of Category 2 and back into a more accessible regulatory category, restoring legal pathways for prescribing. Rogan underscored the problem: much of the market for these compounds moved into a gray or unregulated space, where peptides are sold as “research chemicals” — without quality control, sterility testing, or medical oversight. “That’s ultimately the problem with all this black market stuff… a lot of people are getting bogus peptides and they don’t have any idea how they work, if they work.” — Joe Rogan (summarized). What These Peptides Are and Why They Matter? The 19 peptides referenced on the FDA’s Category 2 list include many compounds widely discussed in regenerative medicine, anti-aging research, and performance recovery. While not FDA-approved drugs, they have generated interest for possible health applications.